Podcast: Michael Kamarck of Merck BioVentures on Opportunities in Biosimilars - - BioPharm International

ADVERTISEMENT

Podcast: Michael Kamarck of Merck BioVentures on Opportunities in Biosimilars


Michael Kamarck, President, Merck BioVentures Opportunities in Biosimilars

With the approval of an abbreviated pathway by which biosimilars may be authorized in the US, the attention is now shifting to the challenges in store for innovator companies in defending their patents and the generics companies in challenging them. In this interview, Michael Kamarck, president of Merck BioVentures and senior vice president, vaccines and biologics manufacturing, discusses the opportunities and challenges in biosimilars.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here